Blood Pressure Medication Recalled Over Possible Contamination
A major recall has been issued for a widely used blood pressure medication after concerns about possible cross-contamination were raised. Glenmark Pharmaceuticals, a global drug maker with U.S. headquarters in Elmwood Park, New Jersey, announced the recall of multiple lots of bisoprolol fumarate and hydrochlorothiazide tablets, sold under the brand name Ziac. According to the Food and Drug Administration, these tablets may have been unintentionally contaminated with traces of another drug, ezetimibe, which is commonly used to manage high cholesterol.
The recall affects tablets in 2.5 mg and 6.25 mg doses, packaged in 30, 100, and 500-count bottles. The impacted lot numbers have expiration dates ranging from November 2025 to May 2026. Glenmark Pharmaceuticals confirmed that testing of reserve samples detected the cholesterol medication, prompting the precautionary withdrawal of the affected products from the market.
Also Read:- Mark Davis Faces Another Raiders Reset Amid Frustration and Uncertainty
- Ronaldo Shines in Abu Dhabi as Al Wahda Face Al-Nassr
The FDA classified this recall as Class III, which indicates that exposure to the product is unlikely to cause serious health consequences. Still, patients taking Ziac are advised to carefully check their medication and consult their pharmacist or healthcare provider if their lot number matches any of the recalled batches. Experts also recommend safely discarding any affected medication to avoid accidental use.
Bisoprolol and hydrochlorothiazide are commonly prescribed together to manage hypertension. Bisoprolol works by blocking beta-1 receptors in the heart, helping the heart beat more regularly, while hydrochlorothiazide promotes urination to remove excess sodium and water from the body. Together, these medications relax blood vessels, lower blood pressure, and reduce the risk of heart attacks and strokes.
While the recall may cause concern among patients, it’s important to note that the FDA does not believe that consuming the affected medication would result in serious harm. Nonetheless, Glenmark Pharmaceuticals and the FDA emphasize that anyone in possession of these lots should confirm their medications and follow the recommended steps for disposal or replacement.
This recall highlights the importance of monitoring medication quality and ensuring patient safety. Even though cross-contamination is rare, it can occur during the manufacturing process when multiple drugs are produced in the same facility. Regulatory agencies continue to oversee drug safety, ensuring that products on the market meet strict standards and minimizing any potential risks for patients.
In summary, thousands of bottles of Ziac have been recalled in the U.S. due to trace contamination with a cholesterol medication. Patients are urged to verify their medication, consult with healthcare professionals, and safely dispose of any affected tablets. While the risk of serious harm is low, precautionary measures remain essential for maintaining safe treatment of high blood pressure.
Read More:
0 Comments